Bare Skin and Laser introduces EXOMIND brain stimulation therapy for depression and emotional wellness

Bare Skin and Laser, a Pennsylvania-based advanced wellness center, has introduced EXOMIND, a non-invasive brain stimulation treatment developed by BTL Industries, aimed at treating depression, anxiety, and cognitive imbalance without medication. The therapy is now available at its flagship clinic in Washington, Pennsylvania, and will be showcased at a public launch event on August 19, 2025.

How Does EXOMIND Work and What Makes It Different From Other Depression Therapies?

EXOMIND uses FDA-cleared electromagnetic pulse technology to activate or regulate neural circuits tied to mood, cognitive performance, and emotional control. The system’s wearable applicator delivers focused magnetic stimulation to specific areas of the brain, mimicking the benefits of traditional transcranial magnetic stimulation (TMS) but with a higher level of personalization and portability. Unlike pharmacologic interventions, which may take weeks to adjust and bring potential side effects, EXOMIND is designed to offer measurable relief in a matter of weeks.

The protocol recommended by clinicians typically involves two 20-minute sessions per week over three weeks. According to internal studies referenced by Bare Skin and Laser, participants in EXOMIND therapy reported improvements in emotional regulation, reduced mental fog, increased focus, and a more balanced mood. These results are aligned with findings from broader research into neuromodulation therapies, which have seen growing validation from the psychiatric and wellness communities.

The treatment is part of a wider movement in behavioral health services that favors non-drug interventions, especially amid rising mental health concerns and widespread interest in bioelectronic medicine. As of 2024, the global neuromodulation devices market was valued at over $6.5 billion and is projected to grow at a CAGR of 9.1% through 2030, according to industry data.

Why Is Bare Skin and Laser Expanding Into Mental Health Treatments?

Founded by nurse practitioner Jodi Ripepi, Bare Skin and Laser initially focused on cosmetic and metabolic wellness services. The clinic’s offerings have included fat-burning programs, hormone balancing, incontinence therapy, and body contouring. With EXOMIND, the company is expanding its service portfolio to address an escalating demand for mental health support in the post-COVID landscape.

“Most people are dealing with some degree of anxiety, depression, or a loss of control these days,” said Ripepi in a statement. “We are pleased to offer the EXOMIND treatment to our patients, who leave our facility feeling an enhanced sense of calm and control.”

The clinic’s move reflects a broader trend in medspa and wellness centers integrating mental health-oriented services—particularly those that avoid the pharmacological route. Across the U.S., lifestyle clinics are leveraging advancements in functional neuroscience and neuromodulation to provide treatments that were once exclusive to psychiatric hospitals and academic research centers.

What to Expect at the EXOMIND Launch Party on August 19?

To promote the new service, Bare Skin and Laser will host an EXOMIND demonstration event at its facility at 100 Adios Drive, Suite 1070, Washington, Pennsylvania. The public launch will take place from 4 to 6 p.m. on August 19, 2025, and is open to community members, prospective patients, and health professionals interested in non-invasive mental health solutions.

Attendees will have an opportunity to learn about the science behind EXOMIND, view live demonstrations on the BTL mobile unit (the “BTL Bus”), and interact with clinicians to assess their suitability for the treatment. The event will also feature raffle prizes, refreshments, and exclusive introductory pricing.

The inclusion of the BTL demo vehicle emphasizes the importance the manufacturer places on consumer education and direct engagement. BTL Industries, a leading developer in aesthetic and physiotherapeutic technologies, is also the company behind Emsculpt and Emsella—two devices already integrated into Bare Skin and Laser’s service menu.

How Does EXOMIND Fit Into the Broader Mental Health Tech Landscape?

EXOMIND enters a competitive yet rapidly evolving sector of digital and device-based mental health interventions. Transcranial and neuromodulation devices have seen increasing interest from both consumers and investors due to their ability to offer targeted relief without systemic drug side effects.

Key competitors in the space include Neuronetics’ NeuroStar system, BrainsWay’s Deep TMS platform, and wearable EEG-guided stimulation tools from startups like Flow Neuroscience and Fisher Wallace. While many of these systems are intended for clinical supervision, EXOMIND aims to strike a balance between medical efficacy and wellness accessibility.

Bare Skin and Laser’s business model—anchoring device-based therapies within a lifestyle wellness setting—reflects the growing fusion of aesthetic medicine with neurocognitive optimization. This approach has drawn interest from insurance partners and private equity groups seeking scalable wellness tech rollouts.

Analyst Take: Can Device-Based Depression Treatments Gain Mainstream Traction?

Although EXOMIND has not yet reported third-party trial results beyond internal clinical validation, market analysts suggest that the early adoption of device-based therapies by integrative wellness centers could reshape the non-clinical mental health landscape. Particularly in suburban and semi-rural settings underserved by psychiatric infrastructure, localized wellness clinics may become key drivers of access.

Investment in neuromodulation startups increased by 18% YoY globally as of Q2 2025, according to data from CB Insights, with a particular surge in U.S.-based companies focusing on portable or wearable brain health devices. While Bare Skin and Laser is not yet part of a national network or franchise chain, its early adoption of EXOMIND positions it as a regional leader in next-gen wellness treatments.

What Comes Next for Bare Skin and Laser After Launching EXOMIND?

While no formal announcement has been made regarding additional clinic locations or franchising, Bare Skin and Laser’s push into neuromodulation could open doors to broader behavioral wellness service offerings. Future additions may include neurofeedback, HRV biofeedback, or even ketamine-assisted therapies, depending on market demand and regulatory climate.

There is also an opportunity to integrate EXOMIND into broader care plans involving hormone rebalancing, weight loss, and stress recovery—an increasingly popular package among midlife and post-menopausal clientele.

With its blend of advanced technology, hands-on care, and community engagement, the clinic is positioned to benefit from rising consumer interest in science-backed, drug-free interventions for emotional health. For BTL Industries, the EXOMIND rollout at Bare Skin and Laser also serves as a proof-of-concept for broader deployment in wellness-focused, non-psychiatric settings.